Clinical Characterization of 66 Patients With Congenital Retinal Disease Due to the Deep-Intronic c.2991+11655A > G Mutation in CEP290Valkenburg, D., van Cauwenbergh, C., Lorenz, B., van Genderen, M. M., Bertelsen, M., Pott, J-W. R., Coppieters, F., de Zaeytijd, J., Thiaden, A. A. H. J., Klaver, C. C. W., Kroes, H. Y., van Schooneveld, M. J., Preising, M., Hoyng, C. B., Leroy, B. P., van den Born, L. I. & Collin, R. W. J., Sep-2018, In : Investigative ophthalmology & visual science. 59, 11, p. 4384-4391 8 p.
Research output: Contribution to journal › Article › Academic › peer-review
Purpose: To describe the phenotypic spectrum of retinal disease caused by the c.2991+1655A>G mutation in CEP290 and to compare disease severity between homozygous and compound heterozygous patients.
Methods: Medical records were reviewed for best-corrected visual acuity (BCVA), age of onset, fundoscopy descriptions. Foveal outer nuclear layer (ONL) and ellipsoid zone (EZ) presence was assessed using spectral-domain optical coherence tomography (SD-OCT). Differences between compound heterozygous and homozygous patients were analyzed based on visual performance and visual development.
Results: A total of 66 patients were included. The majority of patients had either light perception or no light perception. In the remaining group of 14 patients, median BCVA was 20/195 Snellen (0.99 LogMAR; range 0.12-1.90) for the right eye, and 20/148 Snellen (0.87 LogMAR; range 0.22-1.90) for the left. Homozygous patients tended to be more likely to develop light perception compared to more severely affected compound heterozygous patients (P = 0.080) and are more likely to improve from no light perception to light perception (P = 0.022) before the age of 6 years. OCT data were available in 12 patients, 11 of whom had retained foveal ONL and EZ integrity up to 48 years (median 23 years) of age.
Conclusions: Homozygous patients seem less severely affected compared to their compound-heterozygous peers. Improvement of visual function may occur in the early years of life, suggesting a time window for therapeutic intervention up to the approximate age of 17 years. This period may be extended by an intact foveal ONL and EZ on OCT.
|Number of pages||8|
|Journal||Investigative ophthalmology & visual science|
|Publication status||Published - Sep-2018|
- retinal dystrophy, genetic diseases, visual development, retina, low vision, RPE65 MUTATIONS, AMAUROSIS, GENE, DYSTROPHY, IDENTIFICATION, DEGENERATION, MECHANISMS, PHENOTYPE, FEATURES, THERAPY